Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights to its anti-IL-7Rα biologic, bempikibart, from US-based Amgen (NASDAQ: AMGN). The biologic is currently in middle-stage trials for autoimmune diseases. This move follows Amgen’s acquisition of Horizon Therapeutics earlier this year, which had entered into an agreement with Q32 Bio in 2022 that included an option to purchase the bempikibart program.
Terms of Re-acquisition and Future Plans
Under the re-acquisition terms, Q32 Bio will retain the USD 55 million it received in initial consideration and development funding last year, but will forgo future regulatory and commercial milestone payments to Amgen. Q32 Bio now intends to advance bempikibart in two ongoing Phase II studies for atopic dermatitis (AD) and alopecia areata (AA), with anticipated results in the second half of 2024.- Flcube.com
